ADHD attention deficit and hyperactivity disorder
Conditions
Interventions
The intervention will be the use of 5 mg alimemazine, an antihistaminic drug,
once daily for 4 weeks.
ADHD
alimemazine
allergic diseases
Sponsors
Medisch Centrum Leeuwarden
Eligibility
Age
2 Years to 11 Years
Inclusion criteria
Inclusion criteria: The study will include children in whom the diagnosis of ADHD has established by a professional and who use methylphenidate and who have comorbid atopic diseases as atopic eczema, asthma, or allergic rhinitis.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Being diagnosed with any chronic disease other than ADHD, including diabetes and epilepsy. - Being treated with other medications on a daily base. Interval treatment with painkillers, bronchodilators, ointments, drops etc. are allowed. - Unable to fulfill study procedures - Not fluent in Dutch language - Sufficiently treated and no improvement expected, as judged by the parents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary determinant is the score of symptoms of the allergic disease and of ADHD, measured by the SNAP IV Teacher and Parent rating scale, as filled in by parents | — |
Secondary
| Measure | Time frame |
|---|---|
| The score of ADHD symptoms, as rated by the school teachers using the SNAP IV Teacher and Parent rating scale. Frequency of side effects of alimemazine and methylphenidate, measured by a questionnaire on side effects, amount of sleep and sleeping problems. | — |
Countries
The Netherlands
Outcome results
None listed